Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
NCT04404361 · CTI BioPharma · PHASE2 · terminated · last registry update 2024-06-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “decision to close enrollment early” | – | Registry record, CTI BioPharma |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against JAK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-06Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06958211)
- 2025-05-06Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06959225)
- 2025-04-17Results posted on the registry: Novartis Pharmaceuticals, INC424 (NCT03774082)
- 2025-04-15Phase 3 first posted: Douglas D. Fraser, Pirfenidone + Placebo for pirfenidone (NCT06928272)
- 2025-03-20Phase 3 first posted: Hangzhou Highlightll Pharmaceutical Co., Ltd, TLL-018 (NCT06887127)
- 2025-03-12Results posted on the registry: AbbVie, Ruxolitinib + Navitoclax (NCT03222609)
- 2025-03-07Phase 3 first posted: Alfasigma S.p.A., Filgotinib (NCT06865417)
- 2025-03-07Results posted on the registry: AbbVie, Upadacitinib + Corticosteroid (CS) (NCT03725202)
- 2025-02-18Phase 3 first posted: Incyte Corporation, Ruxolitinib + Vehicle Cream (NCT06832618)
- 2025-02-12Results posted on the registry: Adeline Vanderver, MD, Baricitinib (NCT03921554)
- 2025-02-03Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06804811)
- 2024-12-17Results posted on the registry: Medical College of Wisconsin, Pacritinib (NCT04635059)
- 2024-11-22Phase 3 first posted: AbbVie, Placebo + Upadacitinib (NCT06701331)
- 2024-10-29Results posted on the registry: Mayo Clinic, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter + Ruxolitinib Phosphate (NCT03120624)
- 2024-10-28Results posted on the registry: Novartis Pharmaceuticals, Pelabresib + Ruxolitinib (NCT04603495)
- 2024-10-23Phase 3 first posted: Duke University, TNFi (Tumor Necrosis Factor inhibitor) medication + Abatacept (NCT06654882)
- 2024-10-08Phase 3 first posted: Wes Ely, Baricitinib (NCT06631287)
- 2024-09-26Phase 3 first posted: Incyte Corporation, Tacrolimus (Tac) + Methotrexate (MTX) (NCT06615050)
- 2024-08-13Results posted on the registry: Eli Lilly and Company, Baricitinib + Adalimumab (NCT04088409)
- 2024-08-12Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06548360)
- 2024-07-30Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Tofacitinib (NCT03288324)
- 2024-06-17Phase 3 first posted: AbbVie, Upadacitinib + Dupilumab (NCT06461897)
- 2024-05-14Results posted on the registry: Eli Lilly and Company, Baricitinib + Placebo (NCT03899259)
- 2024-04-29Phase 3 first posted: AbbVie, Upadacitinib 15mg Dose + Dupilumab 300mg Dose (NCT06389136)
- 2024-04-18Results posted on the registry: Dana-Farber Cancer Institute, Ruxolitinib + Paclitaxel (NCT02876302)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision